Dominant Optic Atrophy: How to Determine the Pathogenicity of Novel Variants?

Jason A Zehden Subahari Raviskanthan Peter W Mortensen Marc Ferré Pascal Reynier Dan Milea Andrew G Lee

J Neuroophthalmol

Baylor College of Medicine (JZ), Houston, Texas, US; Department of Ophthalmology (SR, PWM, AGL), Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas; MITOVASC Institute (MF, PR, DM), CNRS 6015, INSERM U1083, University of Angers, France ; Singapore National Eye Center (DM), Singapore, Singapore ; Singapore Eye Research Institute (DM), Singapore, Singapore ; Duke-NUS Medical School (DM), Singapore, Singapore ; Copenhagen University Hospital Denmark (DM), Copenhagen, Denmark; Departments of Ophthalmology (AGL), Neurology, and Neurosurgery, Weill Cornell Medicine, New York, New York; Department of Ophthalmology (AGL), University of Texas Medical Branch, Galveston, Texas; University of Texas MD Anderson Cancer Center (AGL), Houston, Texas; Texas A and M College of Medicine (AGL), Bryan, Texas; and Department of Ophthalmology (AGL), The University of Iowa Hospitals and Clinics, Iowa City, Iowa.

Published: June 2022

Download full-text PDF	Source
http://dx.doi.org/10.1097/WNO.0000000000001352	DOI Listing

Publication Analysis

Top Keywords

dominant optic

optic atrophy

atrophy determine

determine pathogenicity

pathogenicity novel

novel variants?

dominant

atrophy

determine

pathogenicity

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!